Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
A phase 2 trial of AST-301 in gastric & gastro-oesophageal junction cancer, run by Aston Sci. Inc., active and no longer recruiting.
Overview
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer is a phase 2 interventional study registered as NCT05771584 by Aston Sci. Inc., with 24 participants enrolled, started 2023-07-04 and due to reach its primary completion in 2027-02-09. Interventions recorded: AST-301 and rhuGM-CSF.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.